Type I Interferons and NK Cells Restrict Gammaherpesvirus Lymph Node Infection

J Virol. 2016 Sep 29;90(20):9046-57. doi: 10.1128/JVI.01108-16. Print 2016 Oct 15.

Abstract

Gammaherpesviruses establish persistent, systemic infections and cause cancers. Murid herpesvirus 4 (MuHV-4) provides a unique window into the early events of host colonization. It spreads via lymph nodes. While dendritic cells (DC) pass MuHV-4 to lymph node B cells, subcapsular sinus macrophages (SSM), which capture virions from the afferent lymph, restrict its spread. Understanding how this restriction works offers potential clues to a more comprehensive defense. Type I interferon (IFN-I) blocked SSM lytic infection and reduced lytic cycle-independent viral reporter gene expression. Plasmacytoid DC were not required, but neither were SSM the only source of IFN-I, as IFN-I blockade increased infection in both intact and SSM-depleted mice. NK cells restricted lytic SSM infection independently of IFN-I, and SSM-derived virions spread to the spleen only when both IFN-I responses and NK cells were lacking. Thus, multiple innate defenses allowed SSM to adsorb virions from the afferent lymph with relative impunity. Enhancing IFN-I and NK cell recruitment could potentially also restrict DC infection and thus improve infection control.

Importance: Human gammaherpesviruses cause cancers by infecting B cells. However, vaccines designed to block virus binding to B cells have not stopped infection. Using a related gammaherpesvirus of mice, we have shown that B cells are infected not via cell-free virus but via infected myeloid cells. This suggests a different strategy to stop B cell infection: stop virus production by myeloid cells. Not all myeloid infection is productive. We show that subcapsular sinus macrophages, which do not pass infection to B cells, restrict gammaherpesvirus production by recruiting type I interferons and natural killer cells. Therefore, a vaccine that speeds the recruitment of these defenses might stop B cell infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Herpesviridae Infections / immunology*
  • Interferon Type I / immunology*
  • Killer Cells, Natural / immunology*
  • Lymph Nodes / immunology*
  • Lymph Nodes / virology*
  • Macrophages / immunology
  • Macrophages / virology
  • Mice
  • Rhadinovirus / immunology*
  • Tumor Virus Infections / immunology*

Substances

  • Interferon Type I

Grants and funding

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.